These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 4007273)

  • 21. Quality assurance of products manufactured by recombinant DNA technology. A European inspector's reflections.
    Witschi T
    Arzneimittelforschung; 1988 Apr; 38(4):592-4. PubMed ID: 3401275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

  • 23. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic stability and product consistency of rDNA-derived biologicals from mammalian cells.
    Bebbington CR; Lambert K
    Dev Biol Stand; 1994; 83():183-4. PubMed ID: 7883094
    [No Abstract]   [Full Text] [Related]  

  • 25. Biological standards and pharmacopoeias.
    Perkins FT
    Ann Ist Super Sanita; 1975; 11(3-4):322-32. PubMed ID: 1234734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral safety of biological products in WHO policy.
    Grachev VP
    Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WHO Expert Committee on Biological Standardization.
    World Health Organ Tech Rep Ser; 2002; 904():i-vi, 1-107. PubMed ID: 11980231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
    Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
    [No Abstract]   [Full Text] [Related]  

  • 30. Canadian regulatory requirements for recombinant fish vaccines.
    Sethi MS; Gifford GA; Samagh BS
    Dev Biol Stand; 1997; 90():347-53. PubMed ID: 9270863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of tests methods in the quality control of biologicals.
    Hendriksen CF
    Dev Biol Stand; 1999; 101():217-21. PubMed ID: 10566796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory perspectives from Japan - comparability of biopharmaceuticals.
    Kawanishi T
    Biologicals; 2006 Mar; 34(1):65-8. PubMed ID: 16330220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meeting the regulatory requirements for pharmaceutical production of recombinant DNA derived products.
    Werner RG; Langlouis-Gau H
    Arzneimittelforschung; 1989 Jan; 39(1):108-11. PubMed ID: 2719737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced process monitoring: the ultimate alternative.
    Neeleman R; Beuvery C
    Dev Biol (Basel); 2002; 111():273-82. PubMed ID: 12678250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 37. Biotechnology: an introduction to recombinant DNA technology and product availability.
    Evens RP; Witcher M
    Ther Drug Monit; 1993 Dec; 15(6):514-20. PubMed ID: 8122286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of quantitative PCR assays for biologicals: quality and safety evaluation.
    Xu Y; Brorson K
    Dev Biol (Basel); 2003; 113():89-98. PubMed ID: 14620857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Quality control of biologic substances produced using technics for recombination of DNA].
    Bull World Health Organ; 1984; 62(2):183-99. PubMed ID: 6610489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.